Navigation Links
Early activation of immune response could lead to better vaccines
Date:8/30/2012

August 30, 2012 (Bronx, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a new "first response" mechanism that the immune system uses to respond to infection. The findings challenge the current understanding of immunity and could lead to new strategies for boosting effectiveness of all vaccines. The study, conducted in mice, published online today in the journal Immunity.

Grgoire Lauvau, Ph.D.One way the immune system protects the body against microbes like bacteria and viruses is with memory CD8+ T cells, so named because they can "remember" the invading organisms. If someone is later infected by that same microbe, memory CD8+ T cells recognize the invaders and multiply rapidly, forming an army of cytotoxic T cells to hunt down and destroy the microbes and the cells they've infected. This highly specific immune response forms the basis for most vaccinesbut it can take several weeks for them to prime the immune system to respond to "real" infections.

This new study shows that the immune system has another, faster method for responding to infections that could be exploited to produce faster-acting vaccines.

"Our research has revealed that pathogen-specific memory CD8+ T cells are reactivated even before they recognize the antigen they previously encountered," said study leader Grgoire Lauvau, Ph.D., associate professor of microbiology and immunology at Einstein. (Antigens are protein fragments of microbes that trigger an immune response.)

Dr. Lauvau and his colleagues found that this fast-acting immune response is orchestrated by a type of white cell called inflammatory monocytes. After the immune system detects an infection, it recruits monocytes to the affected tissues, where they release inflammatory signals called cytokines. Those inflammatory signals not only activate every memory CD8+ T cell that has previously encountered a pathogen but also stimulate the activation of natural killer cells, another type of white blood cell.

The result is a protective immunologic environment capable of defending against microbes of any kindviruses, bacteria or parasites. Only later do memory CD8+ T cells specific for that microbe's antigen begin to multiply, enabling the immune system to launch its focused attack on that particular microbe.

"We're not saying that recognizing the antigen is unimportant in the immune response," says Dr. Lauvau. "You do need the antigen later on, to cause memory CD8+ T cells to multiply and to get full pathogen-specific protection. But it doesn't seem to be needed during the days immediately following re-infection, when this early form of immunity is operating."

"It's too early to apply these findings clinically," said Dr. Lauvau. "For example, we still need to identify all of the cells and signaling molecules that are involved, and learn how and when the immune system switches from the first phase of protection to the second phase, where you have the antigen. But the important concept to take from this study is that it may be possible to improve vaccines by making this early, generalized immune response persist for a longer time until the later, targeted immune response kicks in."


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Early menopause: A genetic mouse model of human primary ovarian insufficiency
2. Mount Sinai researchers solve mystery surrounding the death of two sisters nearly 50 years ago
3. By detecting smallest virus, researchers open possibilities for early disease detection
4. NASA Goddard scientist receives Presidential Early Career Award
5. Do dolphins think nonlinearly?
6. Transcription factor Lyl-1 critical in producing early T-cell progenitors
7. Diet of early human relative Australopithecus shows surprises, says Texas A&M researcher
8. Brain scans detect early signs of autism
9. Mild thyroid dysfunction in early pregnancy linked to serious complications
10. Environmental estrogens affect early developmental activity in zebrafish
11. Autism Speaks awards nearly $2.9 million to fund autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... -- Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) ... financing, raising $35 million from a syndicate including all Series ... ... Atlas Genetics io® system has been completed with the successful ... February 2016.  This new Series D equity issue will finance ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific ... healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices in ... scientific consultants and contractors. This is the latest step in G&L’s expansion of ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
Breaking Biology Technology: